APLI — Appili Therapeutics Inc.

Price Chart

12 months daily · TSX:APLI

Insider Transactions

90-day window · 6 filings

Date	Insider	Role	Nature	Dir.	Shares	Buy Price	Return	Value
Jul 01, 2026	gowd, prakash	—	Comp. Grant	Buy	100,000	—	—	—
Jul 01, 2026	Matkovits, Theresa	—	Comp. Grant	Buy	100,000	—	—	—
Jul 01, 2026	Howling, Kenneth George	—	Comp. Grant	Buy	100,000	—	—	—
Jul 01, 2026	Froehlich, Juergen	—	Comp. Grant	Buy	100,000	—	—	—
Jul 01, 2026	Cilla, Donald	—	Comp. Grant	Buy	75,000	—	—	—
Jul 01, 2026	Bloom, Brian Matthew	—	Comp. Grant	Buy	100,000	—	—	—

Score uses open-market buys only · 0 open-market · 6 plan / compensation shown but not scored · Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.

Score Breakdown

Signal Analyst · $29/mo

Component	Points	Max	Detail
Conviction (unique buyers) ✓ FREE PREVIEW	0	30	No insider activity
Buy/sell ratio		20	0% buys (0B / 0S)
Dollar value		25	No open-market buys
Lobbying activity		15	1 regs
Contract wins		10	None
Insider track record		10	No track record data
Private placements		8	None
Confluence bonus		10	None
Cluster timing (velocity)		10	No coordinated buying cluster detected
Buy/sell reversal pattern		8	No buy/sell reversal pattern
Total	0	100

Unlock Component Detail — CAD $29/mo

Lobbying Registrations

OCL active · 1 registrations

Effective	Registrant	Subject Matter	Institutions	Status

Unlock 1 Registration — CAD $29/mo

Government Contract Wins

90-day window · none found

No government contract wins in the last 90 days. Analyst plan →

Private Placements

12 months · Signal Analyst · $29/mo

Private placement history, deal size, and lock-up expiry tracking. Analyst plan →

Indigenous Consultation

no records on file

No Indigenous consultation records on file for APLI.

SEDAR+ Filings

official filing registry

Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →

Short Interest

CIRO · Jun 30, 2026

Shares short

9,646

Net change

+3,455 (+55.8%)

Short interest rose 56% since the prior report.

History

Jun 30: 9,646

Jun 15: 6,191

May 31: 10,451

May 15: 10,113

Apr 30: 16,609

Apr 15: 13,343

Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).

Clinical Trials

ClinicalTrials.gov · 3 trials

Phase	Status	Trial	Updated
P3	Completed	The Prevent Severe COVID-19 (PRESECO) Study	Mar 2024
P1	Completed	Bioavailability of ATI-1501 With Taste Test Sub Study	Jan 2019
P2	Terminated	Control of COVID-19 Outbreaks in Long Term Care	Feb 2023

Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and terminations are material catalysts for clinical-stage companies — not investment advice.

Boardroom Connections

2 insiders also active elsewhere

Insider	Other boards	Also an insider at
gowd, prakash	1	RX (61)
Bloom, Brian Matthew	1	WOLF (10)

People who file as insiders here and at other TSX/TSXV companies (number in brackets = that company's Confluence Score). A well-connected insider taking a seat at a new junior can be an early tell. Matched by name across SEDI filings; funds and 10%+ holders excluded.

Government Grants & Funding

3 federal awards · $1.2M total

Program / Agreement	Department	Amount	Start
— Contribution	National Research Council Canada	$760K	Jan 2016
— Contribution	National Research Council Canada	$359K	Jan 2016
— Contribution	National Research Council Canada	$50K	Aug 2015

Federal grants & contributions disclosed by the Government of Canada (Proactive Disclosure), matched to this issuer by legal name. Government funding can be a pre-revenue validation and capital signal. Display-only context, not a Confluence Score input.